During the course of the last LO (India, Ministry of Health, 1962, p. 422) . Thus a combination of isoniazid plus thiacetazone is being sold in one Asian country at 13 times a reasonable price (Andersen, 1962 There is a widely current misconception in medical circles in technically advanced countries that the United Nations specialized agencies have almost unlimited funds and that any developing country can obtain all the antituberculosis medicament it requires just for the asking. In fact, the total expenditure on every aspect of tuberculosis control in 1961 by U.N.I.C.E.F., W.H.O., and the U.N. Technical Assistance Fund was about $2,000,000 (International Union Against Tuberculosis, 1961).
Main Priority of Chemotherapy
Considering the available funds, the cost of current chemotherapy, and the consequent drug shortage, the need for a careful order of priorities is obvious. A rational main priority is to give one year of chemotherapy to every newly diagnosed patient with active tuberculosis. In implementing this priority, the regimen for the individual patient will largely depend on the available resources.
If the drug supplies are adequate, then there is no reason why the common policy of the technically advanced countries of beginning with several months of triple chemotherapy with the three standard drugs followed by a two-drug regimen for the rest of the year should not be followed (Table V) . This is, for example, the standard practice in the Government chest-clinic service in Hong Kong. If, however, the budget is smaller it may be possible to give only two-drug therapy, which is likely to be either isoniazid plus P.A.S. for the whole year or isoniazid plus streptomycin for an initial period followed by isoniazid plus P.A.S. With yet smaller budgets an initial period of two-drug therapy followed by isoniazid alone may be all that can be prescribed-a policy strongly advocated by Canetti (1962) . Finally, there will be clinicians who face a situation where, for all practical purposes, the only regimen available to them is isoniazid alone. In this difficult situation, where the practical choice may be to give no chemotherapy at all to the great majority of patients or prescribe isoniazid alone, the clinician can hardly be censured for giving isoniazid alone even though he is departing from the practice of countries with abundant drug supplies. A consideration of the extreme alternatives which face the clinician is relevant. If a clinic in a developing country has a case-load of 2,000 new tuberculous patients a year, the two extreme choices for a clinician with a limited drug budget are: (a) to give best standard chemotherapy (triple-drug therapy for six months followed by isoniazid plus P.A.S. for six months) to about 100 patients in the expectation of attaining quiescent disease in practically every one but leaving 1,900 patients without any chemotherapy at all ; or (b) with the same sum of money purchase drug to treat all 2,000 patients with isoniazid alone, with the aim of attaining quiescence of the disease in a maximum of some 70 % (1,400) of the patients, leaving 600, the great majority of whom will be likely to have isoniazid-resistant infections.
When faced with the choice of leaving 1,900 patients untreated as possible sources of infection in the community or having 600 isoniazid-resistant treatment failures as a possible risk, it seems both unreasonable and unrealistic to expect a clinician not to use isoniazid alone. In contrast to the much-emphasized fear of a build-up of drug-resistance, the continued menace to the community which untreated patients with drug-sensitive organisms constitute is often overlooked. A considerable reduction in the number of infectious cases in the community resulting from the widescale use of chemotherapy might very well lead to major epidemiological benefits and more than offset the community risk of failure-cases excreting isoniazid-resistant bacilli. Further, new antituberculosis drugs might also radically reduce the risk of a build-up of drug resistance. In all events, it is much better to give a continuous course of the best available chemotherapy for a year to every new patient attending a clinic rather than to withhold chemotherapy from many and so drive the patients to take irregular and haphazard treatment from non-medical sources in the local bazaar, as happens so commonly at present.
There is little doubt that a major reason that so many patients present at chest clinics in developing countries with far-advanced disease and an unfavourable prognosis is the frequency with which they are sent away without any treat- (Tuberculosis Chemotherapy Centre, 1960) . In some communities peripheral neuritis will be a complication unless pyridoxine, probably in small dosage, is added Tuberculosis Chemotherapy Centre, 1936b) . As a tuberculosis service expands, chemotherapeutic policy will move towards the best standards of the technically advanced countries.
When drug supplies are adequate for combined chemotherapy to be given to a proportion of cases, the patients should be classified into those likely to respond satisfactorily with isoniazid alone and those more obviously in need of combined chemotherapy.
(a) Of factors in the initial clinical condition, the more extensive cavitated cases and those whose sputum smear is heavily positive should, if possible, receive combined chemotherapy, isoniazid alone being given for limited lesions and for those only scantily positive or negative on smear.
(b) The bacteriological response to treatment can also be used as a guide, combinations being given while the sputum is positive on smear, and once the smear has become negative isoniazid alone.
(c) A history of previous chemotherapy will indicate a greater likelihood of initial drug resistance and hence the desirability of giving more intensive chemotherapy, the aim being to prescribe triple chemotherapy, especially if the disease is extensive.
If further experience shows that isoniazid plus thiacetazone is both effective and non-toxic in areas outside East Africa, this regimen would obviously be preferable to the much more expensive combinations of isoniazid with P.A.S. or with streptomycin and to the regimens of isoniazid alone, which are not so very much cheaper (Table IV) . Similarly, other effective daily regimens and regimens of intermittent chemotherapy would be introduced within the general policy outlined above for obtaining the maximum therapeutic benefit from a limited drug budget.
Although a clinician should aim to give a year of chemotherapy to every patient, he may obtain evidence before then that there is no point in continuing. If at the end of six months of regular therapy the sputum is consistently positive for tubercle bacilli on direct smear examination, it can be predicted with confidence that bacteriological quiescence will not be achieved with the regimen. In addition, a study of the smear results over the period will show either no decline in the bacterial content of the sputum or else a fall in the number of bacilli in the sputum, or their disappearance, followed by an increase-the "fall and rise" phenomenon. A clinician with a limited drug supply should reassess every patient at six months to decide if a second six months of chemotherapy is indicated. (Clearly, negative sputum findings at six months are not an indication for stopping chemotherapy.)
The clinician with limited drug resources has two obligations directly connected with the aim of giving every patient Tuberculou effective combined chemotherapy for a year-namely, (a) constantly to press the authorities to provide adequate supplies of drug for combined chemotherapy for all his patients, and (b) 
the open-negative syndrome the aim must be to give combined chemotherapy for the second year, which has been shown to reduce the relapse rate substantially in patients with the open-negative syndrome (Medical Research Council, 1962) .
The attack rate of tuberculosis in a two-year period in overcrowded close family contacts of infectious cases of tuberculosis, a high-risk group, has been measured in a study in Madras . It was 6.4% for the whole period, being high in the early months of the patient's treatment and declining sharply subsequently, a pattern repeated in a later study (Ramakrishnan et al., 1961b) . Many, though not all, of these contact cases might have been prevented by chemoprophylaxis, although it is uncertain for how long such courses should be given. It seems likely, however, from the above attack rate that even in specially high-risk contact groups chemoprophylaxis for 100 subjects might prevent perhaps 10 cases of tuberculosis developing in a period of follow-up of several years. This is a small gain when balanced against the benefit from treating 100 cases of active tuberculosis, leading to the conclusion that chemoprophylaxis has little place in a programme until the service has reached an advanced stage.
It should be added that both a second year of chemotherapy for quiescent cases and chemoprophylaxis make demands not only on the financial but also on the organizational resources of what is all too commonly an already overstretched clinic service.
Bacteriological and Radiographic Assessment of Progress
In the technically advanced countries many authorities regard frequent cultures and sensitivity tests as essential if the progress of therapy is to be followed satisfactorily. It is common to find in developing countries that few laboratories can culture tubercle bacilli efficiently and that there is no laboratory at all capable of undertaking sensitivity tests, reliable by any reasonable standard, even to the common antituberculosis drugs. (There is still no general agreement concerning the way to perform or interpret drug-sensitivity tests, opinions differing widely from country to country and centre to centre (Canetti, 1957; Rist and Crofton, 1960 (d) Smear-positive but culture-negative specimens may introduce a small element of error. It is, however, exceptional for a patient to produce such specimens frequently, and they are nearly always confined to scanty positive smears (Tuberculosis Chemotherapy Centre, 1959; Medical Research Council, 1962) .
(e) Very occasionally the organisms are not tubercle bacilli at all. For example, leprosy bacilli must be borne in mind in endemic areas, but the diagnosis can usually be made clinically.
It is important that the smear service should be capable of processing large numbers of specimens reliably. A fluorescence microscopy service (Holst et al., 1959) has the special advantages that it is relatively easy to check a sample of the smears, both positive and negative, at the end of every day's readings to ensure that the technician's standards are maintained, and that it is also more economical than a ZiehlNeelsen service.
Cultures
Culture results during treatment usually add little to the findings on smear examination. They sometimes show that for a month or two a patient who has become bacteriologically negative on smear examination is still excreting tubercle bacilli. Also, a bacteriological relapse may be detected a month or two earlier by culture than by smear. It is, however, unusual for the sputum to remain consistently positive on culture but negative on smear.
Sensitivity Tests
Since reliable sensitivity tests are for all practical purposes not available, physicians in developing countries currently have no alternative but to depend on clinically available assessments. A careful history may reveal that a patient has had previous chemotherapy and with what drugs, indicating possible initial drug resistance. If, during treatment, a patient has sputum which is fairly consistently positive on smear at the end of six months of chemotherapy or later, it can be concluded that the disease is very unlikely to attain bacteriological quiescence on the regimen and that the patient has, in all probability, organisms resistant to the drug or drugs prescribed . If a patient has a bacteriological relapse while on chemotherapy, then, provided the prescribed medicament has in fact been taken, the organisms are in all probability resistant to the drugs in the regimen (Devadatta et al., 1961 ; Velu et al., 1961b; Medical Research Council, 1962 As laboratories become able to undertake sensitivity tests it is preferable to use them for surveys to measure the prevalence of drug resistance in the community (Fox, 1963, p. 130) rather than to study individual patients and their response to chemotherapy. When a stage is reached which makes it possible to use sensitivity tests in the individual patient, it is still most valuable to use them to investigate pretreatment specimens. The tests are more informative in patients with a history of previous chemotherapy than in patients without a history, since the former are much more likely to have drug-resistant strains, making the choice of a chemotherapeutic regimen of special importance. The next stage would be to use sensitivity tests on pretreatment specimens in patients with no history of previous chemotherapy, and last of all would come the use of sensitivity tests to follow the actual progress of treatment.
Sanatorium and Clinic Treatment
The current role of sanatorium treatment is a problem of major importance. As already indicated, many developing countries have very few sanatorium beds. Should these countries embark on programmes of sanatorium construction or should they concentrate their resources on ambulatory chemotherapy ? The decision must be made both on medical and economic grounds.
Medical Considerations
To determine the medical place of sanatorium treatment three questions must be considered: (1 (Devadatta et al., 1961 
Construction Costs
In Kenya the cost of sanatorium construction per bed, according to Ministry of Works building standards, is about $2,800, whereas a chest clinic in Nairobi capable of carrying a case-load of 1,000 new cases of tuberculosis a year cost less than 10 times that sum ($28,000) to build and equip (P. W. Kent, personal communication, 1962 Centre, 1959) .
There are some developing countries which in the past concentrated primarily on a sanatorium service and which are currently not able materially to increase their annual expenditure on tuberculosis. These countries might, in fact, expand their service by actually shutting sanatorium beds in order to free finances for the ambulatory treatment of a much larger number of patients. The time has come when, in the light of modern chemotherapy, every developing country must review its balance between sanatorium beds and facilities for ambulatory treatment.
Unfortunately some developing countries are still unduly sanatorium-orientated in their planning. Thus it was recommended (India, Ministry of Health, 1962, p. 250) that simultaneously with the expansion of the B.C.G. vaccination and clinic programme a main aim should be for a tuberculosis bed strength of not less than 100,000, representing an increase of 70,000 beds, and for 50,000 beds for isolation (it The organization of clinics has been discussed elsewhere (Fox, 1963, pp. 119-134) , but reference need be made here to the two keys to successful domiciliary treatment, which are: (a) the continuous provision of effective chemotherapy for an adequate period of time, and (b) ensuring that as much as possible of the prescribed medicament is actually taken by the patient. The available resources must be directed to see that these two aspects receive maximum attention. With this in view, clinics should be orientated to the supervision of the self-administration of medicaments by checks of the stocks of pills at surprise visits to the home and by testing urine specimens obtained at the same time for anti-tuberculosis medicament (Fox, 1962a) . The value of such tests in supervising chemotherapy cannot be overstressed, since from the results it is possible to classify patients as "regular" or "irregular" takers of drugs, permitting greater concentration on supervising the irregular patients. As successful intermittent regimens become available (Tuberculosis Chemotherapy Centre, 1963a) entirely supervised administration of medicaments will be possible, necessitating a reorientation of clinic organization and staffing.
Conclusion
The developing countries have a wide spectrum of resources with, at one extreme, for all practical purposes no tuberculosis service, and at the other extreme a service which rivals those of many technically advanced countries. Although this lecture has mainly been centred around the countries at the lower end of the scale, clearly countries with greater resources can approach closer the policies of the technically advanced countries and might especially wish to do so in the management of drug-resistant cases. Even so, the general principles which I have set out still apply.
Finally, tuberculosis is usually one of a number of major health problems, and the expenditure on it must be related to a careful and realistic assessment of the overall health priorities of the community concerned.
Summary
Many developing countries are desperately short of funds for their health services and have major shortages of all cadres of medical, nursing, and technical staff.
Physicians treating tuberculosis in developing countries must be highly selective in their choice and application of facilities which exist in technically advanced countries.
The cost of antituberculosis medicaments is a very important consideration in developing countries.
The main priority of chemotherapy is to give every newly diagnosed case of active tuberculosis a year of uninterrupted chemotherapy with the best regimen which the budgetary permits.
The regimen will change as resources improve. It is necessary to educate the authorities and general public concerning the importance of adequate chemotherapy for tuberculosis.
Subsidiary targets of chemotherapy are (a) to have drugs for reserve regimens; (b) to give a second year of chemotherapy for quiescent cases-namely. isoniazid alone if there is no residual cavitation at one year and combined chemotherapy if there is ; and (c) chemoprophylaxis of high-risk groups.
During treatment bacteriological examinations are more informative than radiography, and progress can adequately be assessed by smear examinations, which are very cheap. Initially, cultures should be reserved for diagnostic purposes and sensitivity tests for the measurement of the prevalence of drug resistance in the community.
A consideration of the results of controlled comparisons of sanatorium and clinic treatment, of rest in bed and ambulation in sanatorium, of the relapse rates in patients, and of the risk to contacts, as well as the economics of sanatorium and clinic construction and treatment, leads to the conclusion that developing countries should concentrate on ambulatory domiciliary chemotherapy.
Expenditure on tuberculosis must be related to the overall health priorities of the community.
Although the views expressed in this lecture are my own, they have crystallized as a result of a period of several years of work as a W.H.O. field-staff member and from many conversations with Indian, W.H.O., and M.R.C. colleagues.
